Analysts’ updated eps estimates for Friday, October 6th:

Goldman Sachs Group, Inc. (The) assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR). The firm issued a sell rating on the stock.

Alliance Data Systems Corporation (NYSE:ADS) had its buy rating reaffirmed by analysts at Keefe, Bruyette & Woods. The firm currently has a $300.00 price target on the stock.

Agnico Eagle Mines Limited (NYSE:AEM) (TSE:AEM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Earnings estimates for Agnico-Eagle for the third quarter have been going down of late. Agnico-Eagle maintains a solid exploration budget and is reinvesting in its assets to expand output. It is making a good progress with its key growth projects and is also expanding mine life across a number of properties. The company has outperformed the industry it belongs to over the last six months. However, Agnico-Eagle is exposed to a volatile gold pricing environment. The company's lower expected production and higher anticipated costs may affect its performance in 2017.”

American International Group (NYSE:AIG) had its buy rating reiterated by analysts at Keefe, Bruyette & Woods. They currently have a $75.00 price target on the stock.

Ares Capital Corporation (NASDAQ:ARCC) had its buy rating reiterated by analysts at Keefe, Bruyette & Woods. The firm currently has a $18.50 target price on the stock.

Broadcom Limited (NASDAQ:AVGO) had its buy rating reissued by analysts at Bank of America Corporation. They currently have a $300.00 price target on the stock.

Goldman Sachs Group, Inc. (The) assumed coverage on shares of AveXis (NASDAQ:AVXS). Goldman Sachs Group, Inc. (The) issued a buy rating on the stock.

Boeing Company (The) (NYSE:BA) had its buy rating reissued by analysts at Cowen and Company. Cowen and Company currently has a $315.00 price target on the stock.

bluebird bio (NASDAQ:BLUE) had its outperform rating reaffirmed by analysts at Leerink Swann. The firm currently has a $145.00 price target on the stock, up from their previous price target of $120.00.

Goldman Sachs Group, Inc. (The) started coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN). Goldman Sachs Group, Inc. (The) issued a buy rating on the stock.

TCG BDC (NASDAQ:CGBD) had its buy rating reiterated by analysts at Keefe, Bruyette & Woods. The firm currently has a $20.00 price target on the stock.

Chimera Investment Corporation (NYSE:CIM) had its hold rating reaffirmed by analysts at Keefe, Bruyette & Woods. They currently have a $18.50 target price on the stock.

Costco Wholesale Corporation (NASDAQ:COST) had its buy rating reaffirmed by analysts at UBS AG. The firm currently has a $190.00 target price on the stock.

Curtiss-Wright Corporation (NYSE:CW) had its buy rating reiterated by analysts at Deutsche Bank AG. The firm currently has a $125.00 target price on the stock.

Cosan Limited (NYSE:CZZ) was downgraded by analysts at Morgan Stanley from an overweight rating to an equal weight rating.

Deckers Outdoor Corporation (NYSE:DECK) had its hold rating reaffirmed by analysts at Robert W. Baird. Robert W. Baird currently has a $67.00 price target on the stock.

Dynex Capital (NYSE:DX) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $7.25 target price on the stock.

First Data Corporation (NYSE:FDC) had its buy rating reiterated by analysts at Keefe, Bruyette & Woods. The firm currently has a $21.00 price target on the stock.

Ferrellgas Partners, L.P. (NYSE:FGP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “In last three months, Ferrellgas Partners’ units have gained more than the industry it belongs to. The partnership is working to drive growth through organic initiatives and acquisitions. It is also focused on cost containment efforts, which are likely to partially offset the impact of erratic weather conditions. The company also benefits from its strong propane distribution network. The fiscal 2017 weather in Ferrellgas’ Partners service territories were 18% warmer than normal, which adversely impacted the financial performance. The persistent pricing pressure in the commodity market resulted in project delays and cancellations, adversely impacting partnership’s long-term growth prospects. Loss of a major customer account is also adversely impacting the performance of the partnership.”

Golub Capital BDC (NASDAQ:GBDC) had its hold rating reiterated by analysts at Keefe, Bruyette & Woods. They currently have a $19.50 target price on the stock.

GAIN Capital Holdings (NYSE:GCAP) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $7.00 target price on the stock.

Ladenburg Thalmann Financial Services assumed coverage on shares of Gladstone Capital Corporation (NASDAQ:GLAD). The firm issued a neutral rating on the stock.

Alphabet (NASDAQ:GOOG) had its buy rating reiterated by analysts at Wells Fargo & Company.

Huntington Ingalls Industries (NYSE:HII) had its hold rating reaffirmed by analysts at Cowen and Company. The firm currently has a $225.00 target price on the stock.

Goldman Sachs Group, Inc. (The) assumed coverage on shares of Incyte Corporation (NASDAQ:INCY). Goldman Sachs Group, Inc. (The) issued a buy rating on the stock.

Goldman Sachs Group, Inc. (The) assumed coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS). Goldman Sachs Group, Inc. (The) issued a sell rating on the stock.

Kinross Gold Corporation (NYSE:KGC) (TSE:K) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Kinross has outperformed the industry it belongs to over a year. Kinross is making steady progress in advancing the projects that give it a strong growth profile among leading gold producers. The Tasiast expansion is expected to significantly contribute to the company’s future growth. The company also remains focused on managing costs and improving cash flow. However, Kinross remains exposed to a sluggish global economy and volatile gold prices. The company needs to improve its reserve base significantly for future growth. “

Marathon Petroleum Corporation (NYSE:MPC) was upgraded by analysts at Edward Jones from a hold rating to a buy rating.

Novartis AG (NYSE:NVS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu, and the recently approved Kisqali. The recent approval of Kymriah for acute lymphoblastic leukemia is a major boost for Novartis given the potential in the CAR T therapy space.Growth drivers like Cosentyx and Entresto, more than offset the impact of generic erosion, mainly due to Glivec. Cosentyx hit blockbuster status in 2016. Earlier, Novartis announced that it is mulling strategic options for its lagging eye-care unit Alcon which includes retaining the business, or a separation via capital market transactions such as a spin-off or an initial public offering. The company will elaborate on its plans for Alcon by end of the year. We are also impressed by the progress in the biosimilars portfolio as the company is on track to launch five more biosimilars by 2020. Shares of the company have outperformed the industry so far in 2017.”

Goldman Sachs Group, Inc. (The) assumed coverage on shares of Spark Therapeutics (NASDAQ:ONCE). Goldman Sachs Group, Inc. (The) issued a buy rating on the stock.

Potbelly Corporation (NASDAQ:PBPB) had its hold rating reiterated by analysts at Maxim Group. They currently have a $11.00 price target on the stock. The analysts wrote, “We maintain our Hold rating and $11 price target on Potbelly Corporation (PBPB) following news late yesterday that the company reached an agreement with activist investor Ancora Advisors.””

Polaris Industries (NYSE:PII) had its neutral rating reissued by analysts at Northcoast Research.

Goldman Sachs Group, Inc. (The) started coverage on shares of Sage Therapeutics (NASDAQ:SAGE). They issued a buy rating on the stock.

Sonic Corp. (NASDAQ:SONC) had its buy rating reissued by analysts at Oppenheimer Holdings, Inc.. Oppenheimer Holdings, Inc. currently has a $29.00 target price on the stock.

Goldman Sachs Group, Inc. (The) initiated coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT). Goldman Sachs Group, Inc. (The) issued a buy rating on the stock.

TCP Capital Corp. (NASDAQ:TCPC) had its buy rating reissued by analysts at Keefe, Bruyette & Woods. The firm currently has a $18.00 target price on the stock.

The Hanover Insurance Group (NYSE:THG) had its hold rating reaffirmed by analysts at Keefe, Bruyette & Woods. They currently have a $91.00 target price on the stock.

Tetra Tech (NASDAQ:TTEK) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Over the past six months, Tetra Tech’s shares have charted a strong upward trajectory, outperforming the industry’s average return. Tetra Tech’s robust financial health, strong backlog levels and diligent capital deployment strategies signal brighter days ahead. Tetra Tech is enjoying steady top-line growth and improved operating efficiency resulting from cost-management initiatives. The company remains bullish about its growth across all four client sectors and expects U.S. state and local clients to be its strongest growth drivers. However, softness in the domestic oil and gas segment and general economic conditions may weigh down on the company’s financials, going forward. This apart, the cyclical nature of the key markets served by the company poses a sustained threat to stable growth of the company. Decreased consumer confidence and stringent competition may also add to the company’s woes.”

Piper Jaffray Companies began coverage on shares of UMB Financial Corporation (NASDAQ:UMBF). Piper Jaffray Companies issued a neutral rating and a $74.00 price target on the stock.

Receive News & Ratings for Acorda Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.